BJMO - volume 12, issue 6, october 2018
T. Gevaert MD, PhD, L. Libbrecht MD, PhD, E. Lerut MD, PhD, B. Weynand MD, PhD, M. Lammens MD, PhD, S. Verschuere MD, PhD, C. Mattelaer MD, B. Lelie MD, J. Eben MD, L. Martinez , M-A. van Caillie MD, S. Rorive MD, PhD, S. Verbeke MD, PhD, M. Baldewijns MD, PhD
The Belgian Working Group on Uropathology has agreed upon a dataset for prostate core needle biopsy reporting, based on existing international guidelines, recent scientific insights, national survey analysis and panel discussion, with the focus on a user- and receptor-friendly format. This dataset should encourage standardised structured reporting of prostate biopsies in the Belgian healthcare system, aiming to improve the quality of individual pathology reports and to provide real benefit for the clinical management of patients and secondary users. Therefore the Belgian Working Group on Uropathology recommends implementing this dataset in each Belgian pathology lab, in close consultation with the entire clinical team involved in the treatment of the prostate cancer patient.
(BELG J MED ONCOL 2018;12(6):279–286)
Read moreBJMO - volume 10, issue 7, november 2016
S. Elsen PhD, E. Lerut MD, PhD, B. Van Cleynenbreugel MD, PhD, F. Van der Aa MD, PhD, H. Van Poppel MD, PhD, P.A. de Witte PhD
The diagnosis of non-muscle-invasive bladder cancer using the standard white-light cystoscopy technique is not optimal and leads to underdiagnosis of some of the tumours. Therefore, in this thesis, the use of Evans blue dye as a diagnostic tool to aid bladder cancer detection during white-light cystoscopy was investigated using a rat orthotopic bladder cancer model. The results show that Evans blue might have great potential to assist detection of bladder cancer in a clinical setting.
(BELG J MED ONCOL 2016;10(7):281–284)
Read moreBJMO - volume 10, issue 4, july 2016
L. Spans PhD, E. Lerut MD, PhD, S. Joniau MD, PhD, F. Claessens PhD
Whole exome sequencing was performed on 38 high-risk prostate cancer samples. We confirmed recurrent mutations in prostate cancer-specific genes, but also identified genes not reported to be mutated, like TET1. This DNA hydroxymethylase converts methylcytosines to hydroxymethylcytosines as a first step in DNA demethylation. By immunohistochemistry, we detected decreased TET1 protein levels in tumour compared to surrounding non-tumour tissue. DNA hydroxymethylation followed the same course. Furthermore, TET1 mRNA expression levels are an independent predictor of metastasis-free survival in a larger retrospective cohort, indicating an important role for TET1 and hydroxymethylation in prostate cancer.
The LNCaP and C4-2B cell lines form an excellent preclinical model to study the development of metastatic castration-resistant prostate cancer. Both exome and transcriptome sequencing was performed: more than half of the mutations found in the exomes were confirmed in the RNA-sequencing data. Combining C4-2B-specific mutations with differentially expressed genes allowed the detection of changes in focal adhesion and ECM-receptor interactions, which might contribute to the metastatic potential of C4-2B cells.
(BELG J MED ONCOL 2016;10(4):139–142)
Read moreBJMO - volume 6, issue 3, june 2012
G. De Win MD, T. Van den Broeck , B. Van Cleynenbreugel MD, PhD, F. Claus MD, PhD, E. Lerut MD, PhD
Schistosomiasis is rarely diagnosed in Western European countries. However, due to the popularity of exotic vacations, more and more western patients can get infected by schistosomiasis. Awareness of this disease is important, as an infection can lead to non-transitional cell bladder carcinoma in the long run (squamous cell carcinoma; SCC). In this article, we present a rare case of urogenital schistosomiasis in a 27-year old Belgian male. Extensive patient history together with eosinophil count and bladder biopsy, is the key to making the diagnosis. Medical treatment with praziquantel is often sufficient. (BELG J MED ONCOL 2012;6:97–101)
Read moreBJMO - volume 6, issue 2, april 2012
T. Gevaert MD, PhD, H. Van Poppel MD, PhD, S. Joniau MD, PhD, D. De Ridder MD, PhD, E. Lerut MD, PhD
For more than four decades the Gleason score is the most widely accepted histopathological grading system for prostate cancer. It is a 5-tier grading system that correlates with tumour differentiation and is solely based on architectural patterns within the tumour. Although robust over time, revision of Gleason grading became unavoidable as diagnosis and treatment of prostate cancer also underwent an enormous evolution over time. In 2005 the International Society of Urological Pathology (ISUP) proposed several modifications to the Gleason system which should keep this grading system timely. This review compares the original system to the modified Gleason system and especially focuses on the prognostic relevance of the modifications. It further deals with the question if the Gleason system will be able to keep its prominent role in the diagnostic and prognostic algorithm for prostate carcinoma, especially in the nearby molecular era. (BELG J MED ONCOL 2012;6:45–51)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
